Journal
BIOMOLECULES
Volume 12, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/biom12050711
Keywords
nanobodies; pancreatic cancer; patient derived orthotopic xenograft; CEA; fluorescenceguided-surgery; fluorescence; near-infrared; IRDye800CW; tumor labeling
Categories
Funding
- National Institute of Health [T32CA121938, R01CA256973]
- VA Merit review [1 I01 BX003856-01A1, 1 I01 BX004494-01]
Ask authors/readers for more resources
Tumor-specific targeting can be enhanced with fluorescent nanobodies, allowing for rapid localization and labeling of pancreatic cancer tumors. The fluorescence signal is durable, and both targeting and imaging can be performed on the same day as surgery.
Tumor-specific targeting with fluorescent probes can enhance contrast for identification of cancer during surgical resection and visualize otherwise invisible tumor margins. Nanobodies are the smallest naturally-occurring antigen-binding molecules with rapid pharmacokinetics. The present work demonstrates the efficacy of a fluorescent anti-CEA nanobody conjugated to an IR800 dye to target and label patient derived pancreatic cancer xenografts. After intravenous administration, the probe rapidly localized to the pancreatic cancer tumors within an hour and had a tumor-tobackground ratio of 2.0 by 3 h. The fluorescence signal was durable over a prolonged period of time. With the rapid kinetics afforded by fluorescent nanobodies, both targeting and imaging can be performed on the same day as surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available